Related Experiment Videos
[Comparative study between ibopamine and captopril in mild and moderate heart failure. A double-blind study]
S R Arcensio1, A C Barretto, F Szambock
1Instituto do Coração do Hospital das Clínicas-FMUSP.
Arquivos Brasileiros De Cardiologia
|November 1, 1994
Summary
Ibopamine and captopril both improved congestive heart failure symptoms and exercise capacity. These heart failure treatments demonstrated similar efficacy in enhancing cardiac function without increasing arrhythmias.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) significantly impacts patient quality of life and prognosis.
- Effective pharmacological interventions are crucial for managing CHF symptoms and improving cardiac function.
Purpose of the Study:
- To compare the effects of ibopamine and captopril on symptoms, exercise capacity, and myocardial response in patients with CHF.
- To evaluate the safety and efficacy of these two treatments in heart failure management.
Main Methods:
- A double-blind, parallel randomized study involving 18 patients (functional class II or III CHF).
- Patients received either captopril (50 mg tid) or ibopamine (100 mg tid) for three months.
- Evaluations included symptom assessment, stress tests, echocardiography (Echo), and Holter monitoring.
Main Results:
- Both ibopamine and captopril groups showed clinical improvement.
- Exercise time increased significantly in both groups following treatment.
- Echocardiography revealed improvements in left ventricular dimensions and ejection fraction for both treatments.
- The incidence of ventricular arrhythmias was comparable between the captopril and ibopamine groups.
Conclusions:
- Ibopamine effectively improved cardiac function, exercise tolerance, and ejection fraction in CHF patients.
- The cardiac benefits of ibopamine were comparable to those of captopril.
- Neither ibopamine nor captopril led to an increased incidence of arrhythmias, suggesting a favorable safety profile for both in this patient cohort.